rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SPRY
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      ARS Pharmaceuticals: Neffy Is Gaining Traction, But Revenue Growth Needs To Catch Up
      16h agoSeeking AlphaSPRY
      ARS Pharmaceuticals Analysts Cut Their Forecasts After Downbeat Q3 Results
      Nov 6BenzingaSPRY
      Raymond James downgrades ARS Pharmaceuticals stock rating on weak sales
      Nov 6Investing.comSPRY
      ARS Pharmaceuticals Inc (SPRY) Q3 2026 Earnings Call Highlights: neffy Market Share Tops 5% as ...

      ARS Pharmaceuticals Inc (SPRY) posted 42% year-over-year growth in neffy end-user demand and cut SG&A by over 40%, keeping it on track for cash flow breakeven by year-end 2027.

      Nov 6Yahoo FinanceSPRY
      ARS Pharmaceuticals Q3 Earnings Call Highlights
      Nov 6Yahoo FinanceSPRY
      ARS Pharmaceuticals Q3 2026 Earnings Call Transcript
      Nov 5BenzingaSPRY
      ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates
      Nov 5Yahoo FinanceSPRY
      ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results
      Nov 5Yahoo FinanceSPRY
      ARS Pharma (SPRY) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 5The Globe and MailSPRY
      ARS Pharmaceuticals: Lawsuits And Cash Burn Are Priced In, Yet The Stock Keeps Falling

      ARS Pharmaceuticals' neffy faces slow adoption and insurance hurdles but shows potential for significant market share and revenue. Read why SPRY stock is a Buy.

      Nov 3Seeking AlphaSPRY
      ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
      Oct 29Yahoo FinanceSPRY
      ARS Pharma to Report Third Quarter 2026 Financial Results
      Oct 28Yahoo FinanceSPRY
      Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm Before Lead Plaintiff Deadline on October 5, 2026
      Oct 2BarchartSPRY
      SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
      Oct 1MorningstarSPRY
      Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Securities Class Action Deadline - Contact the Firm Before October 5, 2026
      Sep 30BarchartSPRY
      Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights
      Sep 28BarchartSPRY
      Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026
      Sep 25BarchartSPRY
      Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights

      Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailSPRY
      Kaplan Fox Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Seek Leadership in a Securities Fraud Lawsuit by October 5, 2026
      Sep 22BarchartSPRY
      Kaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026

      Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailSPRY
      Kaplan Fox & Kilsheimer LLP Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before October 5, 2026

      NewMediaWire Press Release.

      Sep 21The Globe and MailSPRY
      SPRY Stockholders with Large Losses Should Contact Robbins LLP About Leading the ARS Pharmaceuticals Inc. Class Action Before the October 5, 2026 Deadline
      Sep 21MorningstarSPRY
      Kaplan Fox & Kilsheimer LLP Reminds Investors of a Securities Class Action Against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and Lead Plaintiff Deadline on October 5, 2026
      Sep 17BarchartSPRY
      ARS Pharma at Cantor Global Healthcare: provider push lifts neffy
      Sep 11Investing.comSPRY
      Kaplan Fox Shareholder Alert: Deadline to Lead in the Securities Fraud Lawsuit Against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) is October 5, 2026

      Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

      Sep 11The Globe and MailSPRY
      SueWallSt Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - SPRY
      Sep 10MorningstarSPRY
      SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
      Sep 6MorningstarSPRY
      Kaplan Fox Continues to Remind ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors of the Lead Plaintiff Deadline on October 5, 2026
      Sep 3BarchartSPRY
      SPRY UPCOMING DEADLINE: SueWallSt Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class Action - Contact the Firm
      Sep 3MorningstarSPRY
      SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
      Sep 2MorningstarSPRY
      SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
      Sep 2MorningstarSPRY
      Kaplan Fox Continues to Alert Investors of a Securities Class Action Deadline on October 5, 2026 Against ARS Pharmaceuticals Inc. (NASDAQ: SPRY)
      Sep 1BarchartSPRY
      ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
      Sep 1Yahoo FinanceSPRY
      Kaplan Fox Continues to Alert Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Class Action Deadline on October 5, 2026

      Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

      Aug 27The Globe and MailSPRY
      SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY
      Aug 27MorningstarSPRY
      Levi & Korsinsky Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - SPRY
      Aug 26MorningstarSPRY
      Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Seeking Recovery to Contact the Firm Before October 5, 2026

      Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

      Aug 25BarchartSPRY
      ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share

      On August 13, ARS Pharmaceuticals (NASDAQ:SPRY) held its second-quarter 2026 earnings call, the first for new President and CEO Donn Casale. He used it to lay out three priorities: sharper commercial targeting for neffy, tighter financial discipline, and a pipeline push into chronic spontaneous urticaria. The quarter itself showed a company still early in proving […]

      Aug 21Yahoo FinanceSPRY

      This is the newest page. Registered accounts read further back.